Microba FY26 Revenue Falls 5.8%, Loss Widens 38.7%, Core Testing Revenue Hits $8.6 Million

Strategic Pivot Drives Core Testing Growth Despite Overall Revenue Decline

Microba Life Sciences (ASX:MAP) closed FY26 with total revenue down 5.8% to $14.76 million, dragged by a planned phase-out of legacy products. However, the company’s sharpened focus on core microbiome testing paid dividends, with continuing product revenue climbing 53% to $12.7 million and core testing revenue soaring 92% to approximately $8.6 million. Core tests sold reached 22,418, up 78% year-on-year, with an exit run-rate exceeding 25,000 tests annually, cementing core testing as the majority of group revenue.

This transition marks the twelfth consecutive quarter of core testing growth, underscoring Microba’s success in repositioning its portfolio around scalable, high-growth diagnostic products.

Loss Widens Statutory But Underlying Performance Improves

The statutory net loss after tax widened 38.7% to $20.7 million, reflecting non-cash and non-recurring items including a $1.5 million foreign currency loss and a $0.75 million impairment related to discontinued product technology. Adjusting for these, Microba’s underlying loss improved 11% to $18.8 million, supported by a 7% reduction in operating expenses to $29.9 million. The company’s cost-streamlining program, targeting $7 million in annual savings fully implemented in H1 FY27, leverages AI across customer support, engineering, and science teams to drive efficiency.

Capital Raises Bolster Balance Sheet Ahead of Key Product Launch

Microba strengthened its capital position with $13 million gross equity proceeds during FY26, including a $5 million placement led by strategic partner Sonic Healthcare Limited (ASX:SHL), which subscribed for $4.1 million across placements. Post-year-end, the company completed a further $0.8 million raise via placement and share purchase plan, issuing over 16 million shares and 100 million attaching options exercisable at $0.0625.

This capital injection provides the working capital runway to accelerate clinical adoption and commercial growth initiatives, notably the upcoming launch of the Microba GI Navigator diagnostic product, scheduled for October 2026.

Clinical Adoption Gains Momentum in Australia and UK

Microba’s Microbiome Explorer test recorded a record Q4 with 5,311 tests sold in Australia, up 54% year-on-year, supported by 901 active ordering clinicians and 43 enterprise-clinic accounts signed since November 2025. These accounts sold over 5,600 tests with an estimated ordering potential above 24,000 tests per annum, while the broader key-account pipeline exceeds 175 targets, representing potential for over 80,000 tests annually.

In the United Kingdom, the company saw a record Q4 of 825 tests, up 92% year-on-year, with 313 active ordering clinicians, an 85% increase. The UK market is tracking ahead of the Australian adoption curve at a similar stage post-launch.

Therapeutics and New Diagnostic Launch on Horizon

Microba is advancing its therapeutics portfolio with lead asset MAP-315, a Phase 2-ready live biotherapeutic for ulcerative colitis, supported by positive clinical trial outcomes in related sectors. The Phase 1 trial results for MAP-315 were provisionally accepted for publication in Nature Communications. The company commenced a formal partnering campaign in July 2026, aiming for licensing or non-dilutive equity structures, preserving core intellectual property and minimizing further R&D spend.

The upcoming launch of Microba GI Navigator, powered by the company’s proprietary Clinical Logic Engine, is positioned as a category-defining test targeting patients with unresolved gastrointestinal disorders. Early access sales have begun with 35 units sold to leading practitioners across Australia and the UK, indicating initial clinical traction.

Board Changes and Merger Discussions

During FY26, two long-serving non-executive directors, Richard Bund and Hyungtae Kim, resigned, with Stéphane Chatonsky appointed as an independent non-executive director, bringing over 25 years of healthcare and pathology investment experience. Post-year-end, Microba entered preliminary, non-binding discussions with Genetic Signatures Limited (ASX:GSS) regarding a potential merger. These talks remain incomplete with no binding agreements or certainty of a transaction.

Outlook and Financial Position

Microba enters FY27 with a clean revenue base, a structurally lower cost base, and momentum in core testing growth. The company targets full group cash flow break-even on a run-rate basis in calendar 2027, supported by the cost reduction program and revenue growth from scaled core testing and supplements. Cash and equivalents stood at $7.95 million as of 30 June 2026.

While the company acknowledges a material uncertainty regarding going concern dependent on execution and capital availability, management remains confident in its ability to continue as a going concern, supported by demonstrated capital raising capability and operational adjustments.

Investors should watch closely how the GI Navigator launch performs commercially and whether the enterprise-clinic channel matures as anticipated to drive the company to break-even. The progress of therapeutics partnering and any developments in merger discussions with Genetic Signatures will also be key catalysts in the near term.

Microba’s journey reflects the challenges of category creation in clinical microbiome testing, balancing investment in innovation and market development with the imperative to reduce losses and reach sustainable profitability.